Abstract
| Original language | Undefined |
|---|---|
| Pages (from-to) | 370-378 |
| Journal | Biomaterials |
| Volume | 53 |
| DOIs | |
| Publication status | Published - 2015 |
Keywords
- METIS-310435
- IR-95812
Cite this
}
Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. / Hu, Q.; Rijcken, Cristianne J.; Bansal, Ruchi; Hennink, Wim E.; Storm, Gerrit; Prakash, Jai.
In: Biomaterials, Vol. 53, 2015, p. 370-378.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles
AU - Hu, Q.
AU - Rijcken, Cristianne J.
AU - Bansal, Ruchi
AU - Hennink, Wim E.
AU - Storm, Gerrit
AU - Prakash, Jai
PY - 2015
Y1 - 2015
N2 - Treatment with chemotherapy such as docetaxel (DTX) is associated with significant toxicity and tumour recurrence. In this study, we developed DTX-entrapped core-cross-linked polymeric micelles (DTX-CCL-PMs, 66 nm size) by covalently conjugating DTX to CCL-PMs via a hydrolysable ester bond. The covalent conjugation allowed for sustained release of DTX under physiological conditions in vitro. In vivo, DTX-CCL-PMs demonstrated superior therapeutic efficacy in mice bearing MDA-MB-231 tumour xenografts as compared to the marketed formulation of DTX (Taxotere®). Strikingly, a single intravenous injection of DTX-CCL-PMs enabled complete regression of both small (∼150 mm3) and established (∼550 mm3) tumours, leading to 100% survival of the animals. These remarkable antitumour effects of DTX-CCL-PMs are attributed to its enhanced tumour accumulation and anti-stromal activity. Furthermore, DTX-CCL-PMs exhibited superior tolerability in healthy rats as compared to Taxotere. These preclinical data strongly support clinical translation of this novel nanomedicinal product for the treatment of cancer
AB - Treatment with chemotherapy such as docetaxel (DTX) is associated with significant toxicity and tumour recurrence. In this study, we developed DTX-entrapped core-cross-linked polymeric micelles (DTX-CCL-PMs, 66 nm size) by covalently conjugating DTX to CCL-PMs via a hydrolysable ester bond. The covalent conjugation allowed for sustained release of DTX under physiological conditions in vitro. In vivo, DTX-CCL-PMs demonstrated superior therapeutic efficacy in mice bearing MDA-MB-231 tumour xenografts as compared to the marketed formulation of DTX (Taxotere®). Strikingly, a single intravenous injection of DTX-CCL-PMs enabled complete regression of both small (∼150 mm3) and established (∼550 mm3) tumours, leading to 100% survival of the animals. These remarkable antitumour effects of DTX-CCL-PMs are attributed to its enhanced tumour accumulation and anti-stromal activity. Furthermore, DTX-CCL-PMs exhibited superior tolerability in healthy rats as compared to Taxotere. These preclinical data strongly support clinical translation of this novel nanomedicinal product for the treatment of cancer
KW - METIS-310435
KW - IR-95812
U2 - 10.1016/j.biomaterials.2015.02.085
DO - 10.1016/j.biomaterials.2015.02.085
M3 - Article
VL - 53
SP - 370
EP - 378
JO - Biomaterials
JF - Biomaterials
SN - 0142-9612
ER -